Corvus Pharmaceuticals, Inc. (CRVS)
D
Pipeline Grade
Financial Position (from SEC Filings)
$40.1M
Cash & Equivalents
$10.4M
Quarterly Burn Rate
12 mo
Est. Cash Runway
$1,318M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2027-06-01 | Phase2 Readout | — |
Active Clinical Trials (3)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06561048 | Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Speci... | PHASE3 | Recruiting | 150 |
| NCT07441395 | Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD | PHASE2 | Recruiting | 200 |
| NCT03952078 | A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma | PHASE1 | Active Not Recruiting | 151 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.